| abstract |
The object of the present invention is to provide an effective anti-HCV therapy. The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a mixture thereof, which comprises serine protease activity, in particular the activity of hepatitis C virus NS3-NS4A protease. Inhibits. Thus, they act by interfering with the hepatitis C virus life cycle and are useful as antiviral agents. The present invention further relates to pharmaceutically acceptable compositions containing the compounds described above, either for ex vivo use or administration to patients suffering from HCV infection. The invention further relates to a process for preparing the above compounds. The invention also relates to a method of treating HCV infection in a patient by administering a pharmaceutical composition containing a compound of the invention. [Selection figure] None |